Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this
press release are forward looking and reflect numerous assumptions and involve
a variety of risks and uncertainties, many of which are beyond our control and
may cause actual results to differ materially from stated expectations. For
example, there can be no assurance that temperature modulation therapies will
gain increasing acceptance and use, that alternatives to InnerCool's products
will not be perceived as better, safer or less expensive, that results or
trends observed in one clinical study will be reproduced in subsequent
studies, that necessary regulatory approvals will be obtained, or that our own
actual or proposed products and treatments will prove to be sufficiently safe
and effective and will gain market acceptance. Actual results may also differ
substantially from those described in or contemplated by this press release
due to risks and uncertainties that exist in our operations and business
environment, including, without limitation, our limited experience in the
development, testing and marketing of therapeutic hypothermia devices and
whether our efforts to launch new devices and systems will be successful or
completed within the time frames contemplated, risks and uncertainties that
are inherent in the conduct of human clinical trials, including the timing,
costs and outcomes of such trials, our dependence upon proprietary technology,
our history of operating losses and accumulated deficits, our reliance on
collaborative relationships and critical personnel, and current and future
competition, as well as other risks described from time to time in filings we
make with the Securities and Exchange Commission
'/>"/>
| SOURCE Cardium Therapeutics Copyright©2008 PR Newswire. All rights reserved |